Artículo
Comprando el artículo el PDF del mismo podrá ser descargado
Precio 19,34 €
Comprar ahora
array:24 [ "pii" => "S2173578622001019" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2022.09.002" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1503" "copyright" => "AEU" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2023;47:1-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210480622001759" "issn" => "02104806" "doi" => "10.1016/j.acuro.2022.07.003" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1503" "copyright" => "AEU" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2023;47:1-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">EDITORIAL</span>" "titulo" => "Comentario editorial sobre «Dosis reducida vs. dosis completa de BCG en el cáncer de vejiga: revisión sistemática y metaanálisis»" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "3" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Editorial commentary on: “Reduced vs full-dose BCG therapy in bladder cancer: A systematic review and meta-analysis”" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D.M. Carrión, B. Pradere, F. Soria, F. del Giudice, M. Moschini" "autores" => array:5 [ 0 => array:2 [ "nombre" => "D.M." "apellidos" => "Carrión" ] 1 => array:2 [ "nombre" => "B." "apellidos" => "Pradere" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Soria" ] 3 => array:2 [ "nombre" => "F." "apellidos" => "del Giudice" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Moschini" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578622001019" "doi" => "10.1016/j.acuroe.2022.09.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578622001019?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480622001759?idApp=UINPBA00004N" "url" => "/02104806/0000004700000001/v1_202301030813/S0210480622001759/v1_202301030813/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2173578622000804" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2022.08.005" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1493" "copyright" => "AEU" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Urol Esp. 2023;47:4-14" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Reduced- vs full-dose BCG in bladder cancer: A systematic review and meta-analysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "4" "paginaFinal" => "14" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dosis reducida vs. dosis completa de BCG en el cáncer de vejiga: revisión sistemática y metaanálisis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2424 "Ancho" => 2675 "Tamanyo" => 381806 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">PRISMA flow diagram.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Verri, M. Baboudjian, P. Diana, A. Gallioli, A. Territo, J.M. Gaya, J. Huguet, O. Rodriguez-Faba, J. Palou, A. Breda" "autores" => array:10 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Verri" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baboudjian" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Diana" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Gallioli" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Territo" ] 5 => array:2 [ "nombre" => "J.M." "apellidos" => "Gaya" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Huguet" ] 7 => array:2 [ "nombre" => "O." "apellidos" => "Rodriguez-Faba" ] 8 => array:2 [ "nombre" => "J." "apellidos" => "Palou" ] 9 => array:2 [ "nombre" => "A." "apellidos" => "Breda" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578622000804?idApp=UINPBA00004N" "url" => "/21735786/0000004700000001/v2_202310271302/S2173578622000804/v2_202310271302/en/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S2173578622000804" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2022.08.005" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1493" "copyright" => "AEU" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Urol Esp. 2023;47:4-14" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Reduced- vs full-dose BCG in bladder cancer: A systematic review and meta-analysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "4" "paginaFinal" => "14" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dosis reducida vs. dosis completa de BCG en el cáncer de vejiga: revisión sistemática y metaanálisis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2424 "Ancho" => 2675 "Tamanyo" => 381806 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">PRISMA flow diagram.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Verri, M. Baboudjian, P. Diana, A. Gallioli, A. Territo, J.M. Gaya, J. Huguet, O. Rodriguez-Faba, J. Palou, A. Breda" "autores" => array:10 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Verri" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baboudjian" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Diana" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Gallioli" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Territo" ] 5 => array:2 [ "nombre" => "J.M." "apellidos" => "Gaya" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Huguet" ] 7 => array:2 [ "nombre" => "O." "apellidos" => "Rodriguez-Faba" ] 8 => array:2 [ "nombre" => "J." "apellidos" => "Palou" ] 9 => array:2 [ "nombre" => "A." "apellidos" => "Breda" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578622000804?idApp=UINPBA00004N" "url" => "/21735786/0000004700000001/v2_202310271302/S2173578622000804/v2_202310271302/en/main.assets" ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Editorial commentary on: “Reduced vs full-dose BCG therapy in bladder cancer: A systematic review and meta-analysis”" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "3" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "D.M. Carrion, B. Pradere, F. Soria, F. del Giudice, M. Moschini" "autores" => array:5 [ 0 => array:4 [ "nombre" => "D.M." "apellidos" => "Carrion" "email" => array:1 [ 0 => "dmcarrion@torrejonsalud.com" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "B." "apellidos" => "Pradere" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 2 => array:3 [ "nombre" => "F." "apellidos" => "Soria" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 3 => array:3 [ "nombre" => "F." "apellidos" => "del Giudice" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 4 => array:3 [ "nombre" => "M." "apellidos" => "Moschini" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] ] "afiliaciones" => array:8 [ 0 => array:3 [ "entidad" => "Department of Urology, Torrejon University Hospital, Universidad Francisco de Vitoria, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto de Cirugía Urológica Avanzada (ICUA), Clínica CEMTRO, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "European Association of Urology — Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Department of Urology UROSUD, Croix Du Sud Hospital, Quint-Fonsegrives, France" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Department of Urology, Medical University of Vienna, Vienna, Austria" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Department of Urology, AOU Citta della Salute e della Scienza, Torino School of Medicine, Turin, Italy" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Department of Urology, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy" "etiqueta" => "h" "identificador" => "aff0040" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Comentario editorial sobre «Dosis reducida vs. dosis completa de BCG en el cáncer de vejiga: Revisión sistemática y metaanálisis»" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We read with great interest the study performed by Verri et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> where they performed a systematic review and meta-analysis on a controversial topic: the efficacy and safety of reduced-dose bacilli Calmette-Guérin (BCG) instillations for bladder cancer in comparison with the standard full-dose.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Although the standard dosage has been empirically proposed, and can differ among the different strains available (without definitive superiority among available strains),<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> BCG remains the standard of care for preventing recurrences, and lowering the risk of progression of high-risk non-muscle invasive bladder cancer (HR-NMIBC) and improving survival outcomes.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Clinicians face two main problems while using BCG therapy: the side effects that may lead to discontinuation and its worldwide shortage.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Studies have shown that compliance with the entire maintenance therapy with BCG is poor in patients with HR-NMIBC, ranging from 29% to 59%.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> On the other hand, a few years ago, Sanofi Pasteur (Lyon, France) discontinued their production of BCG Connaught strain causing a worldwide shortage of BCG.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">To overcome the BCG shortage, it has been suggested to decrease the number and dose of instillations. The recently published NIMBUS trial, a multicentric randomized clinical trial (RCT), showed that a reduced number of instillations (3 and further 2 instillations at 3, 6, and 12 months) was significantly inferior to the standard schedule (6 instillations for induction and 3 instillations at 3, 6, and 12 months for maintenance) regarding the primary endpoint of time to first recurrence.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Despite the results from this high level of evidence study, results of previously published systematic reviews and meta-analyses were conflictive.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9–11</span></a> Although a recent meta-analysis by Choi et al. which included nine RCTs with 1217 patients (from 1992 to 2016) found a higher recurrence rate in the reduced-dose group without difference in progression, cancer-specific survival or overall survival, the authors did not performed any subgroup analysis between the studies including only induction and those including induction and maintenance therapy.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Verri et al. have reviewed the literature up to January 2022, founding 17 studies that met their inclusion criteria (prospective or retrospective comparison studies on oncologic and/or toxicologic outcomes), from 1992 to 2021, involving a total of 3757 patients. The results of their primary analysis showed that a reduced-dose was associated with a significantly higher recurrence rate (OR: 1.19; 95% CI: 1.03–1.36; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.02), although no association was found in progression, metastasis, death from bladder cancer, or death from any cause. The most interesting and innovative part of their results stands in the preplanned subgroup analysis according to the schedule and regimen used (induction only or induction<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>maintenance). Indeed, they found that the reduced-dose was associated with higher recurrence rates in the studies that evaluated an induction schedule only (OR: 1.70; 95% CI: 1.19–2.42; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.004), but found no difference if a maintenance schedule was performed (OR: 1.07; 95% CI: 0.96–1.29; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.17). Therefore, these results offer new evidence to consider a potential benefit of reduced-dose regimen as long as a maintenance therapy and a strict follow-up are applied. Nevertheless, some limitations need to be underlined, first the inclusion of prospective and retrospective studies in their analysis may affect the results in the subgroup analysis. Second, we need to keep in mind that proposing a reduced regimen should be offered only in very selective cases, when BCG instillations are well tolerated and only in BCG shortage circumstances as the highest level of evidence remains against its common use. Additionally, genomic changes over the past 40–50 years have led to several worldwide available sub-strains of BCG, which ultimately may have altered or imbalanced the compared strain’s potential efficacy. Available evidence is indeed suggesting efficacy and safety of some strains may lead to a more robust immune response earlier on during induction therapy course balanced by some loss of efficacy during maintenance due to a decrease in the immune response over time. By contrast, other strains seem presenting specific long-acting immunogenic proprieties following the induction phase, supporting the idea that it needs a long-term duration therapy to exhibit its proper therapeutic potential.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a> Future cumulative evidence will indeed need to further explore the relative influence immune response of different BCG strains in association with their dose and schedule administration.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The landscape for newer treatments for high-risk NMIBC, not only to enhance BCG therapy but to be effective when failures and resistances are detected is constantly evolving. Some strategies are enhancing BCG activity inside the bladder with hydrogels, the use of drug delivery carriers such as nanocarriers or liposomes, combining BCG with immune checkpoint inhibitors, and genetically modifying BCG strains that could improve the effectiveness as well as reducing side effects.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">There is a need to improve our armamentarium for the treatment of HR-NMIBC with effective and safe treatments and the future might be bright with the actual drugs evaluated in enrolling studies. Nevertheless, BCG is the best treatment available and altought the best schedule and regimen remains debated, it could be probably considered to offer a reduce dose when a maintenance therapy can be proposed in selected patients.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dosis reducida vs. dosis completa de BCG en el cáncer de vejiga: revisión sistemática y metaanálisis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Verri" 1 => "M. Baboudjian" 2 => "P. Diana" 3 => "A. Gallioli" 4 => "A. Territo" 5 => "J.M. Gaya" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuroe.2022.08.005" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2023" "volumen" => "47" "paginaInicial" => "4" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37078844" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Unda-Urzaiz" 1 => "J.M. Cozar-Olmos" 2 => "B. Miñana-Lopez" 3 => "J. Camarero-Jimenez" 4 => "X. Brugarolas-Rossello" 5 => "C. Zubiaur-Libano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2017.10.003" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2018" "volumen" => "42" "paginaInicial" => "238" "paginaFinal" => "248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29295749" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Babjuk" 1 => "M. Burger" 2 => "O. Capoun" 3 => "D. Cohen" 4 => "E.M. Compérat" 5 => "J.L. Dominguez Escrig" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2021.08.010" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2022" "volumen" => "81" "paginaInicial" => "75" "paginaFinal" => "94" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34511303" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Krajewski" 1 => "O. Rodríguez-Faba" 2 => "A. Breda" 3 => "F. Pisano" 4 => "S. Poletajew" 5 => "A. Tukiendorf" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2019.02.006" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2019" "volumen" => "43" "paginaInicial" => "445" "paginaFinal" => "451" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31155372" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert’s panel. Spanish Association of Urology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.M. Fernández-Gómez" 1 => "J. Carballido-Rodríguez" 2 => "J.M. Cozar-Olmo" 3 => "J. Palou-Redorta" 4 => "E. Solsona-Narbón" 5 => "J.M. Unda-Urzaiz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2013.04.002" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "387" "paginaFinal" => "394" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23773824" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.G. Musat" 1 => "C.S. Kwon" 2 => "E. Masters" 3 => "S. Sikirica" 4 => "D.B. Pijush" 5 => "A. Forsythe" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Clin Outcomes Res CEOR" "fecha" => "2022" "volumen" => "14" "paginaInicial" => "35" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Kazt A. Sanofi’s Halt of BCG Production Worries Bladder Cancer Patients and Urologists. Consulted on July 18th, 2022. Available at: <a target="_blank" href="https://www.onclive.com/view/sanofis-halt-of-bcg-production-worries-bladder-cancer-patients-and-urologists">https://www.onclive.com/view/sanofis-halt-of-bcg-production-worries-bladder-cancer-patients-and-urologists</a>." ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.O. Grimm" 1 => "A.G. van der Heijden" 2 => "M. Colombel" 3 => "T. Muilwijk" 4 => "L. Martínez-Piñeiro" 5 => "M.M. Babjuk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2020.04.066" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2020" "volumen" => "78" "paginaInicial" => "690" "paginaFinal" => "698" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32446864" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Zeng" 1 => "X. Yu" 2 => "C. Ma" 3 => "Z. Zhang" 4 => "R. Song" 5 => "X. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000002176" "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2015" "volumen" => "94" "paginaInicial" => "e2176" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26656345" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Y. Quan" 1 => "C.W. Jeong" 2 => "C. Kwak" 3 => "H.H. Kim" 4 => "H.S. Kim" 5 => "J.H. Ku" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000008300" "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2017" "volumen" => "96" "paginaInicial" => "e8300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29049231" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: systematic review and meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.Y. Choi" 1 => "M.S. Ha" 2 => "J.H. Kim" 3 => "B.H. Chi" 4 => "J.W. Kim" 5 => "I.H. Chang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4111/icu.20210340" "Revista" => array:6 [ "tituloSerie" => "Investig Clin Urol" "fecha" => "2022" "volumen" => "63" "paginaInicial" => "140" "paginaFinal" => "150" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35244987" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): a propensity score matched analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Del Giudice" 1 => "R.S. Flammia" 2 => "B.I. Chung" 3 => "M. Moschini" 4 => "B. Pradere" 5 => "A. Mari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/cancers14040887" "Revista" => array:5 [ "tituloSerie" => "Cancers" "fecha" => "2022" "volumen" => "14" "paginaInicial" => "887" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35205635" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Del Giudice" 1 => "G.M. Busetto" 2 => "M.S. Gross" 3 => "M. Maggi" 4 => "A. Sciarra" 5 => "S. Salciccia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00432-021-03571-0" "Revista" => array:6 [ "tituloSerie" => "J Cancer Res Clin Oncol" "fecha" => "2021" "volumen" => "147" "paginaInicial" => "3073" "paginaFinal" => "3080" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33675400" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Álvarez-Maestro" 1 => "F. Guerrero-Ramos" 2 => "O. Rodríguez-Faba" 3 => "J.L. Domínguez-Escrig" 4 => "J.M. Fernández-Gómez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2020.08.003" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2021" "volumen" => "45" "paginaInicial" => "93" "paginaFinal" => "102" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33012593" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BCG in bladder cancer immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Jiang" 1 => "G. Redelman-Sidi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/cancers14133073" "Revista" => array:5 [ "tituloSerie" => "Cancers (Basel)" "fecha" => "2022" "volumen" => "14" "paginaInicial" => "3073" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35804844" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000004700000001/v2_202310271302/S2173578622001019/v2_202310271302/en/main.assets" "Apartado" => array:4 [ "identificador" => "6293" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000004700000001/v2_202310271302/S2173578622001019/v2_202310271302/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578622001019?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en este medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided. It has high visibility and accessibility and is found in the most important data bases, Medline/Pubmed, Emabase, JCR, Ïndice Médico Español, Índice bibliográfico Español en Ciencias de la Salud (IBECS), Cuiden, Dialnet, Hinari, Scopus, Google Scholar.
Science Citation Index Expanded, Journal of Citation Reports, Index Medicus/MEDLINE, Scopus, EMBASE/Excerpta Medica, IBECS
Ver másEl factor de impacto mide la media del número de citaciones recibidas en un año por trabajos publicados en la publicación durante los dos años anteriores.
© Clarivate Analytics, Journal Citation Reports 2022
SJR es una prestigiosa métrica basada en la idea de que todas las citaciones no son iguales. SJR usa un algoritmo similar al page rank de Google; es una medida cuantitativa y cualitativa al impacto de una publicación.
Ver másSNIP permite comparar el impacto de revistas de diferentes campos temáticos, corrigiendo las diferencias en la probabilidad de ser citado que existe entre revistas de distintas materias.
Ver más¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos